{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T17:49:21Z","timestamp":1780508961499,"version":"3.54.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","physicamedica.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Physica Medica"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ejmp.2026.105795","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T03:15:25Z","timestamp":1774926925000},"page":"105795","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Radiotherapy and nuclear Medicine: Is it time to find a common language? The importance of accumulating doses across various modalities"],"prefix":"10.1016","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3537-3187","authenticated-orcid":false,"given":"Amedeo","family":"Capotosti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerio","family":"Dav\u00ec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2842-0301","authenticated-orcid":false,"given":"Riccardo","family":"Laudicella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Surgo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4241-1364","authenticated-orcid":false,"given":"Maria Paola","family":"Ciliberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Carbonara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiorella Cristina","family":"Di Guglielmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Bonaparte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Moretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8626-0003","authenticated-orcid":false,"given":"Davide","family":"Cusumano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"Fiorentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmp.2026.105795_b0005","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.semradonc.2020.07.002","article-title":"The Radiobiology of Radiopharmaceuticals","volume":"31","author":"Morris","year":"2021","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.ejmp.2026.105795_b0010","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1016\/S1120-1797(22)02202-5","article-title":"MULTI-TREATMENT DOSIMETRIC EVALUATION: 90Y-RADIOEMBOLIZATION WITH PREVIOUS MR-GUIDED EXTERNAL BEAM RADIATION THERAPY","volume":"104","author":"Capotosti","year":"2022","journal-title":"Phys Med"},{"key":"10.1016\/j.ejmp.2026.105795_b0015","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1007\/s00259-021-05345-9","article-title":"EANM position paper on the role of radiobiology in nuclear medicine","volume":"48","author":"Aerts","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ejmp.2026.105795_b0020","doi-asserted-by":"crossref","first-page":"860","DOI":"10.3390\/cancers11060860","article-title":"The 6th R of Radiobiology: Reactivation of Anti-Tumor Immune Response","volume":"11","author":"Boustani","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.ejmp.2026.105795_b0025","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0360-3016(91)90171-Y","article-title":"Tolerance of normal tissue to therapeutic irradiation","volume":"21","author":"Emami","year":"1991","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejmp.2026.105795_b0030","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.ijrobp.2009.09.040","article-title":"Quantitative analyses of Normal Tissue Effects in the Clinic (QUANTEC): an Introduction to the Scientific Issues","volume":"76","author":"Bentzen","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejmp.2026.105795_b0035","unstructured":"Council Directive 2013\/59\/Euratom of 5 December 2013 laying down basic safety standards for protection against the dangers arising from exposure to ionising radiation, and repealing Directives 89\/618\/Euratom, 90\/641\/Euratom, 96\/29\/Euratom, 97\/43\/Euratom and 2003\/122\/Euratom n.d."},{"key":"10.1016\/j.ejmp.2026.105795_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmp.2023.103166","article-title":"EFOMP policy statement NO. 19: Dosimetry in nuclear medicine therapy \u2013 Molecular radiotherapy","volume":"116","author":"Sj\u00f6green-Gleisner","year":"2023","journal-title":"Phys Med"},{"key":"10.1016\/j.ejmp.2026.105795_b0045","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.ijrobp.2023.05.015","article-title":"Preferential Tumor Vascular damage is the Common Antitumor Mechanism of High-Dose Hypofractionated Radiation Therapy: SABR, Spatially Fractionated Radiation Therapy, and FLASH Radiation Therapy","volume":"117","author":"Song","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejmp.2026.105795_b0050","doi-asserted-by":"crossref","first-page":"923","DOI":"10.2967\/jnumed.123.267023","article-title":"Absorbed Dose\u2013Response Relationship in patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with [177 Lu]Lu-DOTATATE: one step closer to Personalized Medicine","volume":"65","author":"Hebert","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ejmp.2026.105795_b0055","doi-asserted-by":"crossref","first-page":"236","DOI":"10.2967\/jnumed.123.265987","article-title":"Prediction of177 Lu-DOTATATE PRRT Outcome using Multimodality Imaging in patients with Gastroenteropancreatic Neuroendocrine Tumors: results from a prospective phase II LUMEN Study","volume":"65","author":"Mileva","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ejmp.2026.105795_b0060","doi-asserted-by":"crossref","DOI":"10.1007\/s00259-025-07378-w","article-title":"Correction to: the LUTADOSE trial: tumour dosimetry after the first administration predicts progression free survival in gastro\u2011entero\u2011pancreatic neuroendocrine tumours (GEP NETs) patients treated with [177Lu] Lu\u2011DOTATATE","volume":"52","author":"Maccauro","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ejmp.2026.105795_b0065","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1259\/0007-1285-62-740-679","article-title":"The linear-quadratic formula and progress in fractionated radiotherapy","volume":"62","author":"Fowler","year":"1989","journal-title":"Br J Radiol"},{"key":"10.1016\/j.ejmp.2026.105795_b0070","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.1007\/s00259-022-05786-w","article-title":"Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients","volume":"49","author":"Sundl\u00f6v","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ejmp.2026.105795_b0075","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1118\/1.2836421","article-title":"Extension of the biological effective dose to the MIRD schema and possible implications in radionuclide therapy dosimetry","volume":"35","author":"Baechler","year":"2008","journal-title":"Med Phys"},{"key":"10.1016\/j.ejmp.2026.105795_b0080","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1007\/s00259-022-05727-7","article-title":"EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands","volume":"49","author":"Sj\u00f6green Gleisner","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ejmp.2026.105795_b0085","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s00259-015-3001-1","article-title":"Renal function affects absorbed dose to the kidneys and haematological toxicity during 177Lu-DOTATATE treatment","volume":"42","author":"Svensson","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ejmp.2026.105795_b0090","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1007\/s00259-008-0778-1","article-title":"Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors","volume":"35","author":"Bodei","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ejmp.2026.105795_b0095","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1053\/j.semnuclmed.2021.11.002","article-title":"Iodine-131 and Iodine-131-Meta-iodobenzylguanidine Dosimetry in Cancer Therapy","volume":"52","author":"Flux","year":"2022","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.ejmp.2026.105795_b0100","unstructured":"de Keizer B, Hoekstra A, Konijnenberg MW, de Vos F, Lambert B, van Rijk PP, et al. Bone Marrow Dosimetry and Safety of High 131I Activities Given After Recombinant Human Thyroid-Stimulating Hormone to Treat Metastatic Differentiated Thyroid Cancer n.d."},{"key":"10.1016\/j.ejmp.2026.105795_b0105","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1007\/s00259-009-1072-6","article-title":"Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate","volume":"36","author":"Forrer","year":"2009","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ejmp.2026.105795_b0110","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1080\/095530000138448","article-title":"Quantitative clinical radiobiology of early and late lung reactions","volume":"76","author":"Bentzen","year":"2000","journal-title":"Int J Radiat Biol"},{"key":"10.1016\/j.ejmp.2026.105795_b0115","article-title":"Stereotactic Inverse Dose Planning after Yttrium-90 Selective Internal Radiation Therapy in Hepatocellular Cancer","volume":"6","author":"Abbott","year":"2021","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.ejmp.2026.105795_b0120","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.semradonc.2008.04.004","article-title":"The Linear-Quadratic Model is an Appropriate Methodology for determining Isoeffective Doses at Large Doses Per Fraction","volume":"18","author":"Brenner","year":"2008","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.ejmp.2026.105795_b0125","unstructured":"Howell RW, Goddu SM, Rao DV. Application of the Linear-Quadratic Model to Radioimmunotherapy: Further Support for the Advantage of Longer-Lived Radionuclides n.d."},{"key":"10.1016\/j.ejmp.2026.105795_b0130","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20180070","article-title":"Radiation repair models for clinical application","volume":"92","author":"Dale","year":"2018","journal-title":"Br J Radiol"},{"key":"10.1016\/j.ejmp.2026.105795_b0135","doi-asserted-by":"crossref","DOI":"10.1088\/1361-6560\/ad70f0","article-title":"Modelling radiobiology","volume":"69","author":"Gardner","year":"2024","journal-title":"Phys Med Biol"},{"key":"10.1016\/j.ejmp.2026.105795_b0140","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.adro.2019.05.007","article-title":"The special Medical Physics Consult Process for Reirradiation patients","volume":"4","author":"Paradis","year":"2019","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.ejmp.2026.105795_b0145","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1259\/bjr\/31372149","article-title":"21 years of Biologically Effective Dose","volume":"83","author":"Fowler","year":"2010","journal-title":"BJR"},{"key":"10.1016\/j.ejmp.2026.105795_b0150","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.semradonc.2019.02.002","article-title":"Deformable Registration for Dose Accumulation","volume":"29","author":"Chetty","year":"2019","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.ejmp.2026.105795_b0155","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/RLU.0000000000004203","article-title":"Dose-limiting Bone Marrow Toxicities after Peptide Receptor Radionuclide Therapy are more Prevalent in Women than in men","volume":"47","author":"Minczeles","year":"2022","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.ejmp.2026.105795_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.102881","article-title":"Gender-dependent radiotherapy: the next step in personalised medicine?","volume":"147","author":"De Courcy","year":"2020","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["Physica Medica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1120179726000827?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1120179726000827?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T12:13:34Z","timestamp":1776773614000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1120179726000827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":32,"alternative-id":["S1120179726000827"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmp.2026.105795","relation":{},"ISSN":["1120-1797"],"issn-type":[{"value":"1120-1797","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radiotherapy and nuclear Medicine: Is it time to find a common language? The importance of accumulating doses across various modalities","name":"articletitle","label":"Article Title"},{"value":"Physica Medica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmp.2026.105795","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Associazione Italiana di Fisica Medica e Sanitaria. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105795"}}